2. Search Result
Search Result
Results for "

Zucker

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

3

Peptides

9

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0442
    Vardenafil
    5 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil
  • HY-B0442A
    Vardenafil hydrochloride
    5 Publications Verification

    		 Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride
  • HY-113422
    Tetrahydrocorticosterone

    		Endogenous Metabolite Glucocorticoid Receptor Inflammation/Immunology
    Tetrahydrocorticosterone is a glucocorticoid. One of its active forms, 5α-Tetrahydrocorticosterone (HY-113364), exerts its effects by binding to the GC receptor and inhibiting inflammatory processes. Tetrahydrocorticosterone is naturally synthesized by the adrenal glands and plays a key role in regulating the metabolism of carbohydrates, proteins and fats .
    Tetrahydrocorticosterone
  • HY-B0442B
    Vardenafil hydrochloride trihydrate
    5 Publications Verification

    		 Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil hydrochloride trihydrate
  • HY-B1415
    Clofibric acid

    Chlorofibrinic acid

    		 PPAR Bacterial SOD Infection Metabolic Disease Cancer
    Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .
    Clofibric acid
  • HY-143312
    V-0219

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    V-0219 is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 potentiates glucose-dependent insulin secretion. V-0219 improves glucose handling in normal and diabetic rodents. V-0219 can be used for the research of obesity-associated diabetes .
    V-0219
  • HY-116239
    Zenarestat
    1 Publications Verification

    		 Aldose Reductase Neurological Disease Metabolic Disease
    Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats .
    Zenarestat
  • HY-143312A
    V-0219 hydrochloride

    		GLP Receptor Metabolic Disease Inflammation/Immunology
    V-0219 hydrochloride is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 hydrochloride potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 hydrochloride potentiates glucose-dependent insulin secretion. V-0219 hydrochloride improves glucose handling in normal and diabetic rodents. V-0219 hydrochloride can be used for the research of obesity-associated diabetes .
    V-0219 hydrochloride
  • HY-147376
    hACC2-IN-1

    		Acetyl-CoA Carboxylase Metabolic Disease
    hACC2-IN-1 is a potent acetyl-CoA carboxylase 2 (ACC2) inhibitor, with an IC50 value of 2.5 μM (hACC2). hACC2-IN-1 could be used for obesity research .
    hACC2-IN-1
  • HY-129736A
    P32/98

    		Dipeptidyl Peptidase Metabolic Disease
    P32/98 a potent inhibitor of dipeptidyl peptidase IV with a Ki value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .
    P32/98
  • HY-144289
    BMS-820132

    		Glucokinase Metabolic Disease
    BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
    BMS-820132
  • HY-B0442AS
    Vardenafil-d5 hydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil-d5 hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil-d5 hydrochloride
  • HY-121827
    LH21
    1 Publications Verification

    		 Cannabinoid Receptor Metabolic Disease
    LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor .
    LH21
  • HY-107054
    ESP-31015

    ETC-1001

    		 PPAR Cardiovascular Disease
    ESP-31015 (ETC-1001) is an orally active and non-fibrate based PPARα agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research .
    ESP-31015
  • HY-14923
    Ilepatril

    AVE 7688

    		 Angiotensin-converting Enzyme (ACE) Metabolic Disease
    Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .
    Ilepatril
  • HY-129736
    P32/98 hemifumarate

    		Dipeptidyl Peptidase Metabolic Disease
    P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a Ki value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .
    P32/98 hemifumarate
  • HY-173503
    DS-1150b

    		GLUT Metabolic Disease
    DS-1150b is an orally active GLUT4 activator. DS-1150b has the activity of activating GLUT4 transport and can promote the translocation of GLUT4 to the cell membrane in skeletal muscle cells. DS-1150b has shown hypoglycemic effects in the Zucker obese rat model and can be used in the study of type 2 diabetes mellitus (T2DM) .
    DS-1150b
  • HY-121796
    Mixanpril

    		Neprilysin Others
    Mixanpril is a compound with the ability to modulate insulin sensitivity and has the activity of regulating insulin sensitivity and femoral blood flow in obese Zucker rats. Mixanpril can affect insulin-mediated glucose disposal in obese Zucker rats and also has a regulatory effect on femoral blood flow, with different effects compared to the ACE inhibitor captopril.
    Mixanpril
  • HY-135238
    (rel)-RSD 921

    PD-117302

    		 Opioid Receptor Others
    (rel)-RSD 921 (PD-117302) is a κ-opioid receptor agonist. (rel)-RSD 921 did not have a greater food-inducing effect in obese than in lean Zucker rats; in both obese and lean Zucker rats, lean rats were more sensitive to its initial food-inducing effect but ultimately ate less.
    (rel)-RSD 921
  • HY-162586
    PDHK-IN-7

    		PDHK Cancer
    PDHK-IN-7 (compound 32) is an inhibitor of pyruvate dehydrogenase kinase with an IC50 value of 17 nM.PDHK-IN-7 activates PDH in rat livers and has a glucose-lowering effect in Zucker fatty rats .
    PDHK-IN-7
  • HY-111294
    ASP4000 hydrochloride

    		Dipeptidyl Peptidase Metabolic Disease
    ASP4000 hydrochloride is a potent, competitive, selective, orally active DPP4 inhibitor with an IC50 value of 2.25 nM against human recombinant DPP4. ASP4000 hydrochloride shows antihyperglycemic activity. ASP4000 hydrochloride can be used in the research of type 2 diabetes .
    ASP4000 hydrochloride
  • HY-P0165B
    Taspoglutide acetate

    ITM077 acetate; R1583 acetate; BIM51077 acetate

    		 GLP Receptor Metabolic Disease
    Taspoglutide (R1583) acetate is an agonist of the glucagon-like peptide 1 receptor (GLP-1R) with an Ki value of 1.1 nM. Taspoglutide acetate induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). Taspoglutide acetate decreases blood levels of glucose and increases blood levels of insulin in a glucose tolerance test in Zucker diabetic obese rats. Taspoglutide acetate reduces blood levels of gastric inhibitory polypeptide (GIP), plasma levels of triglycerides, and body weight in the same model .
    Taspoglutide acetate
  • HY-124399
    N-Octadecyl-N'-propyl-sulfamide

    		Endogenous Metabolite PPAR Metabolic Disease
    Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating lipid and glucose metabolism, and oleoylethanolamide (OEA) is a natural ligand for PPARα. N-Octadecyl-N'-propyl-sulfamide is an analog of OEA and a potent activator of PPARα, with selective binding affinity for PPARα (EC50=100 nM, compared to 120 nM for OEA). N-Octadecyl-N'-propyl-sulfamide (10 mg/kg; ip) inhibits food intake and reduces body weight gain in rats. At a dose of 1 mg/kg, N-Octadecyl-N'-propyl-sulfamide induces satiety, thereby reducing food intake, body weight, and plasma triglyceride concentrations in free-feeding Wistar rats and obese Zucker (fa/fa) rats.
    N-Octadecyl-N'-propyl-sulfamide
  • HY-B0442C
    Vardenafil dihydrochloride

    		Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil dihydrochloride
  • HY-B0442CR
    Vardenafil dihydrochloride (Standard)

    		Reference Standards Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil dihydrochloride (Standard)
  • HY-B0442BR
    Vardenafil hydrochloride trihydrate (Standard)

    		Reference Standards Endogenous Metabolite Phosphodiesterase (PDE) Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil hydrochloride trihydrate (Standard)
  • HY-B0442AR
    Vardenafil hydrochloride (Standard)

    		Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .
    Vardenafil hydrochloride (Standard)
  • HY-B0442R
    Vardenafil (Standard)

    		Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite Metabolic Disease Inflammation/Immunology Endocrinology
    Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6].
    Vardenafil (Standard)
  • HY-182262
    Ro 20-0083

    		Lipase Metabolic Disease
    Ro 20-0083 is an orally active pancreatic lipase inhibitor. Ro 20-0083 inhibits hPancreatic lipase activity, reduces lipid absorption and de novo fatty acid synthesis. Ro 20-0083 decreases food intake in Zucker rats. Ro 20-0083 can be used in obesity-related research .
    Ro 20-0083
  • HY-P11629
    KBP-336

    		Amylin Receptor CGRP Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .
    KBP-336
  • HY-182300
    FE 999011

    		Dipeptidyl Peptidase GLP Receptor Metabolic Disease
    FE 999011 is an orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with IC50 values of 7 nM and 3 nM against human and rat sources, respectively. FE 999011 acts as a glucose tolerance-improving agent and a GLP-1 receptor activator, which reduces blood glucose fluctuation, promotes GLP-1 release and decreases the insulin-glucose ratio. FE 999011 regulates lipid metabolism, delays the onset of diabetes, stabilizes food and water intake, reduces hypertriglyceridemia, prevents the elevation of free fatty acids, and delays the progression of impaired glucose tolerance to disease. FE 999011 can be used in relevant studies of type 2 diabetes .
    FE 999011
  • HY-P11584
    KBP-066A

    		Amylin Receptor CGRP Receptor Metabolic Disease
    KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
    KBP-066A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: